Calyx Medical Imaging extends groundbreaking capability from Ceretype to improve psychiatric treatment outcomes
Calyx, the eClinical and Regulatory solutions and services provider relied on for solving complex data challenges in clinical research, today announced a strategic partnership with Ceretype Neuromedicine, Inc., whose novel functional MRI (fMRI) platform incorporates optimal image acquisition and advanced analytics to de-risk and accelerate the development of psychiatric and neurological therapies.
The current lack of objective biomarkers presents a real challenge for researchers developing treatments for depression/anxiety, schizophrenia, and other neurological/psychiatric conditions such as Parkinson’s Disease. An in-market, audit-cleared “biomarker engine,” the Ceretype platform utilizes cutting-edge fMRI and artificial intelligence (AI) to connect neural circuitry to patient behaviors and treatment outcomes, delivering the objective biologic endpoints researchers need for more precise measurement of treatment effects during central nervous system (CNS) drug development.
“A key component of Calyx’s strategy is partnering with best-in-class technology providers to offer the innovative imaging biomarkers required to find new treatments for unmet medical needs,” said Stephen M. Bravo, MD, Chief Medical Officer at Calyx. “We’re excited to partner with Ceretype and for our customers to leverage their advanced fMRI technology to bring new and more effective psychiatric treatments to market.”
“We’re delighted to combine Ceretype’s neuroscience, biophysics, and computing expertise with Calyx’s 25 years of experience delivering reliable clinical trial imaging,” said Emily Stern, CEO at Ceretype. “Through this partnership, we will achieve our mission of improving psychiatric and neurologic patient outcomes through precision drug development and precision treatment.”
Visit AITechPark for cutting-edge Tech Trends around AI, ML, Cybersecurity, along with AITech News, and timely updates from industry professionals!
